軟部肉腫の世界市場レポート 2025年

軟部肉腫市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.6％で47億6,000万米ドルに成長します。予測期間の主な動向としては、軟部肉腫治療における免疫療法の統合、併用療法の開発、患者中心のケアモデルの重視、リキッドバイオプシーの使用増加、肉腫ゲノミクスの進歩などが挙げられます。

がん罹患率の増加が予想され、軟部肉腫市場の今後の成長を牽引します。がんは、異常な細胞増殖が正常な境界を超え、他の臓器や隣接する身体部位に広がる可能性がある場合に、臓器や組織に発現する多様な疾患群です。がん罹患率の急増は、様々ながん種や肉腫の患者のユニークなニーズに合わせた診断手順、治療アプローチ、支持療法オプションへの需要を強めています。この急増は軟部肉腫市場の拡大に大きく寄与しています。例えば、米国がん協会は、2020年に新たに診断されるがん患者は180万人と報告しています。さらに、米国国立がん研究所による2020年9月のデータでは、1,806,590件の新規がん症例が明らかになり、2019年の1,752,735件から増加し、2020年の米国における男性の診断率が43％であることを示しています。したがって、がん罹患率の上昇が軟部肉腫市場の成長の原動力となっています。

ヘルスケア支出の増加は、軟部肉腫市場の進展を促進すると予想されます。ヘルスケアは、個人またはコミュニティに対する医療サービス、治療、予防ケア、健康問題管理などの組織的な提供を包含します。ヘルスケア支出の増加は、がん研究を含む医学研究への資金提供の増加につながる可能性があります。その結果、軟部肉腫の理解が進み、新たな治療法が発見され、患者の転帰が全体的に改善される可能性があります。例えば、2022年の経済調査によると、2021-22年のインドの医療への公的支出はGDPの2.1％でした。また、ウィリス・タワーズワトソンの調査によると、医療給付費は2021年の8.2％から2022年には8.8％へと世界的に増加し、2023年にはさらに増加して世界平均10％になると予想されています。従って、医療費の増加は軟部肉腫市場の成長を促進することになります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界軟部肉腫PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の軟部肉腫市場：成長率分析
• 世界の軟部肉腫市場の実績：規模と成長, 2019-2024
• 世界の軟部肉腫市場の予測：規模と成長, 2024-2029, 2034F
• 世界軟部肉腫総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の軟部肉腫市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 標的療法
• 化学療法
• 抗血管新生薬
• 放射線治療
• その他の治療法
• 世界の軟部肉腫市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界の軟部肉腫市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門センター
• その他のエンドユーザー
• 世界の軟部肉腫市場、標的療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• チロシンキナーゼ阻害剤（TKI）
• モノクローナル抗体
• 免疫療法剤
• 世界の軟部肉腫市場化学療法の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• ドキソルビシン
• イホスファミド
• ゲムシタビン
• その他の化学療法剤
• 世界の軟部肉腫市場抗血管新生薬のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ベバシズマブ
• パゾパニブ
• アキシチニブ
• その他の抗血管新生剤
• 世界の軟部肉腫市場、放射線治療の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 外部放射線治療（EBRT）
• 近接放射線療法
• 世界の軟部肉腫市場、その他の治療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 手術
• 臨床試験
• 支持療法

第7章 地域別・国別分析

• 世界の軟部肉腫市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の軟部肉腫市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 軟部肉腫市場：競合情勢
• 軟部肉腫市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bayer AG
• Novartis AG
• Sanofi SA
• Bristol Myers Squibb
• AstraZeneca plc
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Merck & Co. Inc.
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Astellas Pharma Inc.
• Daiichi Sankyo Company Limited
• Sun Pharmaceutical Industries Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 軟部肉腫市場2029：新たな機会を提供する国
• 軟部肉腫市場2029：新たな機会を提供するセグメント
• 軟部肉腫市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Soft tissue sarcoma is a type of cancer where malignant cells develop in the soft tissues of the body, and its diagnosis typically involves biopsy techniques. This cancer can originate in various soft tissues, including blood vessels, muscles, nerves, and fat.

The main treatment modalities for soft tissue sarcoma include targeted therapy, chemotherapy, anti-angiogenesis drugs, radiation therapy, and other supportive approaches. Targeted therapy is a treatment method that specifically focuses on the genes, proteins, or tissue environment supporting the growth and survival of cancer cells. It aims to hinder cancer cell proliferation, division, and the creation of new cells. These treatments can be administered through various routes, including oral and parenteral methods. Soft tissue sarcoma treatments are utilized across different healthcare settings, such as hospitals, homecare, specialty centers, and others.

The soft tissue sarcoma market research report is one of a series of new reports from The Business Research Company that provides soft tissue sarcoma market statistics, including soft tissue sarcoma industry global market size, regional shares, competitors with a soft tissue sarcoma market share, detailed soft tissue sarcoma market segments, market trends and opportunities, and any further data you may need to thrive in the soft tissue sarcoma industry. This soft tissue sarcoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The soft tissue sarcoma market size has grown strongly in recent years. It will grow from $3.15 billion in 2024 to $3.42 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to limited treatment options, evolving understanding of sarcoma biology, growth in cancer research funding, rising prevalence of soft tissue sarcoma, and expansion of healthcare infrastructure

The soft tissue sarcoma market size is expected to see strong growth in the next few years. It will grow to $4.76 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to development of targeted therapies for soft tissue sarcoma, increasing focus on personalized medicine, expansion of clinical trials for sarcoma treatments, growing awareness and early detection initiatives.Major trends in the forecast period include integration of immunotherapy in soft tissue sarcoma treatment, development of combination therapies, emphasis on patient-centric care models, rise in the use of liquid biopsies, advances in sarcoma genomics.

The anticipated increase in cancer incidence is poised to drive the future growth of the soft tissue sarcoma market. Cancer, a diverse group of illnesses, manifests in organs or tissues when abnormal cell proliferation exceeds normal boundaries, potentially spreading to other organs or neighboring body parts. The upsurge in cancer incidence intensifies the demand for diagnostic procedures, therapeutic approaches, and supportive care options tailored to the unique needs of patients with various cancer types or sarcoma. This surge significantly contributes to the expansion of the soft tissue sarcoma market. For example, the American Cancer Society reported 1.8 million new cancer cases diagnosed in 2020. Additionally, data from September 2020 by the National Cancer Institute revealed 1,806,590 new cancer cases, indicating a 43% diagnosis rate in men in the United States in 2020, up from 1,752,735 in 2019. Hence, the rise in cancer incidence is a driving force behind the growth of the soft tissue sarcoma market.

The escalating healthcare expenditure is expected to propel the advancement of the soft tissue sarcoma market. Healthcare encompasses the organized provision of medical services, treatments, preventive care, and health issue management for individuals or communities. Higher healthcare expenditures can lead to increased funding for medical research, including cancer research. This, in turn, may result in advancements in understanding soft tissue sarcoma, the discovery of novel treatment modalities, and overall improvement in patient outcomes. For instance, India's public expenditure on healthcare stood at 2.1% of GDP in 2021-22, as per the Economic Survey of 2022. Additionally, a survey by Willis Towers Watson revealed a global increase in healthcare benefit costs from 8.2% in 2021 to 8.8% in 2022, expected to rise further to a global average of 10% in 2023. Therefore, the heightened healthcare expenditure is set to drive the growth of the soft tissue sarcoma market.

Product innovation has emerged as a prominent trend gaining traction in the soft tissue sarcoma market. Major companies within this market are focusing on developing innovative products to fortify their market position. For instance, in November 2023, Mercy, a not-for-profit Catholic health care organization in the US, introduced The Chen Chemotherapy Model-an AI-driven texting program. This program utilizes a smart texting platform to proactively prevent chemotherapy-related hospitalizations by sending daily messages to chemotherapy patients, allowing them to report symptoms and enabling timely intervention. This showcases Mercy's commitment to leveraging technology for enhanced patient care in the chemotherapy field.

Research projects, such as the Leiomyosarcoma Project (LMS), are a focal point for major companies operating in the soft tissue sarcoma market to sustain their market standing. The Leiomyosarcoma Project (LMS) aims to advance scientific understanding and discovery related to leiomyosarcoma-a rare and aggressive cancer originating in smooth muscle cells. Count Me In, a non-profit cancer research initiative, launched the LMS project in September 2022, inviting individuals with this rare cancer to actively participate in research. The initiative seeks to accelerate scientific discovery by engaging patients and encouraging them to share their health data, fostering a collaborative and data-driven approach to improve outcomes for those with rare cancers.

In August 2022, Ipsen SA, a French biopharmaceutical company, acquired Epizyme Inc. for an undisclosed amount. This acquisition grants Ipsen SA access to Epizyme's lead drug, Tazverik (tazemetostat), a first-in-class, chemotherapy-free EZH2 inhibitor, and the oral SETD2 inhibitor, EZM0414. Epizyme Inc., a US-based biopharmaceutical company, specializes in developing drugs for treating soft tissue sarcoma.

Major companies operating in the soft tissue sarcoma market include Pfizer Inc., Johnson & Johnson, Roche Holding AG, F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol Myers Squibb, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Lupin Ltd., Philogen S.p.A., Taiho Pharmaceutical Co.Ltd., Nanobiotix S.A.

North America was the largest region in the soft tissue sarcoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the soft tissue sarcoma market report during the forecast period. The regions covered in the soft tissue sarcoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the soft tissue sarcoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The soft tissue sarcoma includes revenues earned by entities by immunotherapy, hormone therapy, photodynamic therapy, and stem cell transplant. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Soft Tissue Sarcoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on soft tissue sarcoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for soft tissue sarcoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The soft tissue sarcoma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Targeted Therapy; Chemotherapy; Anti-Angiogenesis Drugs; Radiation Therapy; Other Treatments
• 2) By Route Of Administration: Oral; Parenteral; Other Route Of Administrations
• 3) By End-Users: Hospitals; Homecare; Specialty Centers; Other End-Users
• Subsegments:
• 1) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs); Monoclonal Antibodies; Immunotherapy Agents
• 2) By Chemotherapy: Doxorubicin; Ifosfamide; Gemcitabine; Other Chemotherapeutic Agents
• 3) By Anti-Angiogenesis Drugs: Bevacizumab; Pazopanib; Axitinib; Other Anti-Angiogenesis Agents
• 4) By Radiation Therapy: External Beam Radiation Therapy (EBRT); Brachytherapy
• 5) By Other Treatments: Surgery; Clinical Trials; Supportive Care
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Roche Holding AG; F. Hoffmann-La Roche Ltd.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Soft Tissue Sarcoma Market Characteristics

3. Soft Tissue Sarcoma Market Trends And Strategies

4. Soft Tissue Sarcoma Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Soft Tissue Sarcoma Growth Analysis And Strategic Analysis Framework

• 5.1. Global Soft Tissue Sarcoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Soft Tissue Sarcoma Market Growth Rate Analysis
• 5.4. Global Soft Tissue Sarcoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Soft Tissue Sarcoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Soft Tissue Sarcoma Total Addressable Market (TAM)

6. Soft Tissue Sarcoma Market Segmentation

• 6.1. Global Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Targeted Therapy
• Chemotherapy
• Anti-Angiogenesis Drugs
• Radiation Therapy
• Other Treatments
• 6.2. Global Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Route Of Administrations
• 6.3. Global Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Centers
• Other End-Users
• 6.4. Global Soft Tissue Sarcoma Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tyrosine Kinase Inhibitors (TKIs)
• Monoclonal Antibodies
• Immunotherapy Agents
• 6.5. Global Soft Tissue Sarcoma Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Doxorubicin
• Ifosfamide
• Gemcitabine
• Other Chemotherapeutic Agents
• 6.6. Global Soft Tissue Sarcoma Market, Sub-Segmentation Of Anti-Angiogenesis Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bevacizumab
• Pazopanib
• Axitinib
• Other Anti-Angiogenesis Agents
• 6.7. Global Soft Tissue Sarcoma Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• External Beam Radiation Therapy (EBRT)
• Brachytherapy
• 6.8. Global Soft Tissue Sarcoma Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgery
• Clinical Trials
• Supportive Care

7. Soft Tissue Sarcoma Market Regional And Country Analysis

• 7.1. Global Soft Tissue Sarcoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Soft Tissue Sarcoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Soft Tissue Sarcoma Market

• 8.1. Asia-Pacific Soft Tissue Sarcoma Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Soft Tissue Sarcoma Market

• 9.1. China Soft Tissue Sarcoma Market Overview
• 9.2. China Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Soft Tissue Sarcoma Market

• 10.1. India Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Soft Tissue Sarcoma Market

• 11.1. Japan Soft Tissue Sarcoma Market Overview
• 11.2. Japan Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Soft Tissue Sarcoma Market

• 12.1. Australia Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Soft Tissue Sarcoma Market

• 13.1. Indonesia Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Soft Tissue Sarcoma Market

• 14.1. South Korea Soft Tissue Sarcoma Market Overview
• 14.2. South Korea Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Soft Tissue Sarcoma Market

• 15.1. Western Europe Soft Tissue Sarcoma Market Overview
• 15.2. Western Europe Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Soft Tissue Sarcoma Market

• 16.1. UK Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Soft Tissue Sarcoma Market

• 17.1. Germany Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Soft Tissue Sarcoma Market

• 18.1. France Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Soft Tissue Sarcoma Market

• 19.1. Italy Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Soft Tissue Sarcoma Market

• 20.1. Spain Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Soft Tissue Sarcoma Market

• 21.1. Eastern Europe Soft Tissue Sarcoma Market Overview
• 21.2. Eastern Europe Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Soft Tissue Sarcoma Market

• 22.1. Russia Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Soft Tissue Sarcoma Market

• 23.1. North America Soft Tissue Sarcoma Market Overview
• 23.2. North America Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Soft Tissue Sarcoma Market

• 24.1. USA Soft Tissue Sarcoma Market Overview
• 24.2. USA Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Soft Tissue Sarcoma Market

• 25.1. Canada Soft Tissue Sarcoma Market Overview
• 25.2. Canada Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Soft Tissue Sarcoma Market

• 26.1. South America Soft Tissue Sarcoma Market Overview
• 26.2. South America Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Soft Tissue Sarcoma Market

• 27.1. Brazil Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Soft Tissue Sarcoma Market

• 28.1. Middle East Soft Tissue Sarcoma Market Overview
• 28.2. Middle East Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Soft Tissue Sarcoma Market

• 29.1. Africa Soft Tissue Sarcoma Market Overview
• 29.2. Africa Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Soft Tissue Sarcoma Market Competitive Landscape And Company Profiles

• 30.1. Soft Tissue Sarcoma Market Competitive Landscape
• 30.2. Soft Tissue Sarcoma Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Soft Tissue Sarcoma Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Novartis AG
• 31.3. Sanofi SA
• 31.4. Bristol Myers Squibb
• 31.5. AstraZeneca plc
• 31.6. GlaxoSmithKline plc
• 31.7. Takeda Pharmaceutical Company Limited
• 31.8. Eli Lilly and Company
• 31.9. Merck & Co. Inc.
• 31.10. Amgen Inc.
• 31.11. Teva Pharmaceutical Industries Ltd.
• 31.12. Mylan N.V.
• 31.13. Astellas Pharma Inc.
• 31.14. Daiichi Sankyo Company Limited
• 31.15. Sun Pharmaceutical Industries Ltd.

32. Global Soft Tissue Sarcoma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Soft Tissue Sarcoma Market

34. Recent Developments In The Soft Tissue Sarcoma Market

35. Soft Tissue Sarcoma Market High Potential Countries, Segments and Strategies

• 35.1 Soft Tissue Sarcoma Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Soft Tissue Sarcoma Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Soft Tissue Sarcoma Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer